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Polymorphisms in Folate, Pyrimidine, and Purine
Metabolism Are Associated with Efficacy and Toxicity
of Methotrexate in Psoriasis
Emanuela Campalani1, Monica Arenas2, Anthony M. Marinaki2, Cathryn M. Lewis3, Jonathan NWN Barker1
and Catherine H. Smith1
Methotrexate is the gold standard therapy for moderate to severe psoriasis, but there is marked interpersonal
variation in its efficacy and toxicity. We hypothesized that in psoriasis patients, specific common
polymorphisms in folate, pyrimidine, and purine metabolic enzymes are associated with methotrexate efficacy
and/or toxicity. DNA from 203 retrospectively recruited psoriasis patients treated with methotrexate was
collected and genotyped by restriction endonuclease digestion or length polymorphism assays. The reduced
folate carrier (RFC) 80A allele and the thymidylate synthase (TS) 3’-untranslated region (3’-UTR) 6 bp deletion
were associated with methotrexate-induced toxicity (P¼ 0.025 and P¼ 0.025, respectively). RFC 80A and
5-aminoimidazole-4-carboxamide ribonucleotide transformylase (ATIC) 347G were associated with methotrex-
ate discontinuation (P¼ 0.048 and P¼ 0.038). The TS 5’-UTR 28 bp 3R polymorphism correlated with poor clinical
outcome (P¼ 0.029), however, this was not the case when patients with palmoplantar pustular psoriasis were not
included in the analysis. Stronger associations between specific polymorphisms and methotrexate-induced
toxicity and discontinuation were found in a subanalysis of patients on methotrexate not receiving folic acid
supplementation. We have demonstrated preliminary evidence that specific polymorphisms of enzymes
involved in folate, pyrimidine, and purine metabolism could be useful in predicting clinical response to
methotrexate in patients with psoriasis.
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INTRODUCTION
Methotrexate is considered the gold standard therapy for
moderate to severe psoriasis. However, there is a consider-
able interpersonal variation in the therapeutic response and
toxicity profile of this drug. Methotrexate therapy can be
complicated by acute myelosuppression, gastrointestinal
symptoms, and hepatotoxicity, resulting in up to 30% of
patients having to discontinue therapy (Roenigk et al., 1998;
Haustein and Rytter, 2000). A pharmacogenetic study of the
use of methotrexate in psoriasis would allow the develop-
ment of individually tailored drug therapy, therefore maxi-
mizing efficacy and minimizing toxicity.
Although the mechanism of action of methotrexate is not
fully understood, it appears clear that once transported into
the cell by folate-specific carrier mechanisms, methotrexate
interferes with folate metabolism (Figure S1), and that
polymorphisms in the carriers and enzymes involved in this
biological pathway could potentially be responsible for
methotrexate resistance or an increased risk of adverse events
in patients with psoriasis. There is evidence from research in
hematological malignancies (Krajinovic et al., 2002, 2004;
Laverdiere et al., 2002; Aplenc et al., 2005), osteosarcoma
(Ifergan et al., 2003; Flintoff et al., 2004; Serra et al., 2004),
and recently, rheumatoid arthritis (RA) (Kumagai et al., 2003;
Berkun et al., 2004; Dervieux et al., 2004), that polymorphic
variants in some enzymatic targets of methotrexate play an
important role in the individual’s sensitivity to the drug, but
very little is known about their effect in psoriasis patients
taking methotrexate.
The reduced folate carrier (RFC) 80G4A (Arg27His)
single-nucleotide polymorphism (SNP), was significantly
associated with a worse outcome in children with acute
lymphoblastic leukemia who received chemotherapy with
methotrexate (Whetstine et al., 2001; Laverdiere et al., 2002).
More recently, patients diagnosed with RA carrying the
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homozygous variant genotype (RFC 80AA) were found to
have a better clinical response to methotrexate (Dervieux
et al., 2004).
There is evidence that a polymorphism in the promoter
region of the thymidylate synthase gene (TS), a double or
triple tandem 28 bp repeat (2R or 3R), might influence
therapeutic response to methotrexate. The homozygous
3R/3R genotype was associated with increased expression
of the TS gene (Horie et al., 1995; Kawakami et al., 1999).
However, a guanine to cytosine SNP recently identified
within the triple repeat allele (3R G4C) results in a TS
transcriptional activity similar to that of the double repeat
(2R) allele. The 3R/3R genotype was associated with a poor
response to methotrexate therapy in acute lymphoblastic
leukemia (Krajinovic et al., 2002) and RA (Kumagai et al.,
2003; Dervieux et al., 2004). A homozygous 6 bp deletion
(6bp del) at nucleotide 1,494 in the 30-untranslated region (30-
UTR) (TS 30-UTR 6bp ins/del) of the TS gene correlated with a
better therapeutic response to methotrexate in RA (Kumagai
et al., 2003).
The 677C4T (Ala222Val) and 1298A4C (Glu429Ala)
variants in the methylenetetrahydrofolate reductase (MTHFR)
gene have been associated with adverse drug events related
to methotrexate (Chango et al., 2000; Rosenberg et al.,
2002). The MTHFR 677T allele leads to a thermolabile
enzyme variant, with decreased activity and subsequent
increased plasma homocysteine levels, and has been
associated with increased methotrexate toxicity in patients
treated for acute lymphoblastic leukemia (Ulrich et al.,
2001; Chiusolo et al., 2002) and RA (van Ede et al., 2001).
The MTHFR 1298A4C polymorphism leads to a protein
variant with 60% of the activity, which is neither thermo-
labile nor associated with increased plasma homocysteine
levels. However, when combined with the 677T SNP in a
compound heterozygous genotype, MTHFR activity was
significantly decreased with an increased frequency of
methotrexate-induced adverse events (Weisberg et al.,
1998).
Inhibition of 5-aminoimidazole-4-carboxamide ribonu-
cleotide transformylase (ATIC) by methotrexate results in
the accumulation of adenosine, a potent anti-inflammatory
agent (Baggott et al., 1986; Cronstein et al., 1994; Montesinos
et al., 2003). Although the functional consequences of the
ATIC 347C4G (Thr116Ser) SNP are unknown, the homo-
zygous variant genotype 347 GG was associated with
better therapeutic response to methotrexate in patients with
RA (Dervieux et al., 2004).
A functional significance in relation to methotrexate has
also been suggested for adenosine deaminase (ADA), not
directly related to folate metabolism but also involved in
purine metabolism. Activity of this enzyme falls during
methotrexate treatment with a subsequent increase in
adenosine levels (van Ede et al., 2002). A 22G4A SNP leads
to the synthesis of ADA2, a polymorphic variant with a
significantly reduced enzyme activity (Hirschhorn et al.,
1994). ADA2 is predicted to result in increased adenosine
concentrations, and, therefore, might be associated with
a better therapeutic response to methotrexate.
We set out to investigate the potential role of these
common polymorphisms in folate, pyrimidine, and purine
metabolic enzymes in predicting clinical outcome and/or
toxicity owing to therapy with methotrexate in patients with
psoriasis.
RESULTS
203 patients with psoriasis (192 with chronic plaque, 8 with
palmoplantar pustular (PPP), 2 with erythrodermic, and 1
with guttate psoriasis), who had previously or currently been
treated with oral methotrexate were recruited in this study.
Among patients with PPP, four were classified as non-
responders, two as responders, and two as indeterminate. In
total, 193 patients completed 3 months therapy with
methotrexate, and of these, 114 were defined as methotrexate
responders, 44 as non responders, and 35 as indeterminate.
Patients were classified as indeterminate if clinical informa-
tion was not available, incomplete, or did not fulfil the
criteria for the definition of response or non response. Seven
patients out of 203 did not finish a 3-month course with
methotrexate because of intolerable side effects. Clear
information regarding the presence or absence of methotrex-
ate-induced toxicity was available for 188 patients. One
hundred and four patients experienced at least one adverse
event, with 67 having to discontinue the drug (Table S1).
Only two out of 203 patients experienced bone marrow
toxicity and were therefore not analyzed as a separate
subgroup. Ninety-six patients received folic acid 5 mg either
daily or weekly. In each group the majority of patients were
white Caucasian (80–84%), with too few non-Caucasian
patients for allele frequencies to be compared by ethnicity.
Patients who responded to methotrexate or experienced an
adverse event and/or discontinued therapy did not receive
higher doses of the drug (Table S1). Folic acid was not
associated with poor response to methotrexate, although
there was a negative correlation between folate supplemen-
tation and methotrexate withdrawal, with patients not
receiving folic acid significantly more likely to discontinue
therapy (P¼ 0.011, odds ratio (OR)¼2.26[1.19–4.30] 95%
confidence interval (CI)). The therapy discontinuation rate
was 33%, the most frequent reason being nausea (35%),
closely followed by abnormal transaminase levels (30%)
(Table S2).
Impact of RFC, MTHFR, TS, ATIC, and ADA polymorphisms on
methotrexate efficacy
The TS 5’-UTR 3R allele was significantly (P¼ 0.029) more
frequent in patients who did not respond to methotrexate
(64%) than in responders (50%). Although the frequency of
the 3R/3R variant homozygous genotype did not significantly
vary between responders and non-responders, the presence
of one or two 3R alleles (homozygous or heterozygous
variant genotype) was significantly associated with non-
response to therapy (P¼ 0.048, OR¼2.96 [0.96–9.06] 95%
CI). However, when patients with PPP were excluded, the
significance for the TS 5’-UTR 3R allele was lost. The
frequency of the TS 5’-UTR 3RC allele or the TS 3’-UTR 6bp
del allele did not differ significantly between the two patient
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groups. A subanalysis of patients not receiving folic acid
showed that TS 5’-UTR 3R and TS 3’-UTR 6bp del alleles
were more frequent in non-responders (58 and 37%,
respectively) compared with responders (43 and 25%,
respectively), but not significantly so. The MTHFR 677C4T
and MTHFR 1298A4C, ATIC 347C4G, RFC 80G4A and
ADA 22G4A allele or genotype frequencies did not
significantly differ between the two groups, regardless of
whether a dominant or recessive model was applied.
Impact of RFC, MTHFR, TS, ATIC, and ADA polymorphisms on
methotrexate-induced toxicity
The TS 3’-UTR 6bp del polymorphism was significantly more
frequent in patients who experienced an adverse event
(P¼0.025), and this was more likely to be a symptomatic
side effect (P¼0.044) than an alanine transaminase (ALT)
elevation (P¼ 0.126) (Table 1), irrespective of folic acid
supplementation. This was a dominant effect as the frequency
of the variant homozygous and heterozygous genotypes was
significantly higher than the frequency of the wild-type
genotype (P¼ 0.046, OR¼1.86 (1.00–3.44) 95% CI).
Patients with one or more adverse events had a
significantly higher percentage of RFC 80A alleles than those
tolerant to methotrexate (P¼0.025) and this effect was
dominant (P¼0.049, OR¼1.89[0.99–3.61] 95% CI). When
the adverse event group was broken down into specific
events, the RFC 80A allele was more frequent both in patients
with hepatotoxicity (P¼ 0.053) and those with a symptomatic
side effect (P¼0.043) than in tolerant patients, but analysis of
genotype frequencies failed to show any associations
(Table 1). In patients with symptomatic side effects, a joint
analysis of RFC and TS 3’-UTR polymorphisms showed
evidence for epistasis between the loci (P¼0.013), with an
OR of 2.86 for the RFC 80A/TS 3’-UTR 6bp del genotype,
compared to the RFC 80G/TS 3’-UTR 6bp ins genotype. The
frequency of the TS 5’-UTR 2R or 3R alleles, as well as the
3RG4C SNP did not differ significantly between patients
who experienced adverse events and those who did not.
In a subanalysis of patients not on concomitant folic acid
supplementation, allele and genotype distributions were
altered even more (Table S3). The TS 5’-UTR 3R allele was
significantly more frequent in patients who experienced an
adverse event (P¼0.0025), hepatotoxicity (P¼ 0.015), or a
symptomatic side effect (P¼0.0034). Genotypes with at least
one TS 5’-UTR 3R allele were significantly more frequent in
these three groups except among patients with hepatotoxi-
city. ORs calculated for the different genotypes were greater
for the variant homozygous genotype than for variant
homozygous and heterozygous genotypes combined, sug-
gesting a recessive effect: the TS 5’-UTR 3R/3R genotype
was significantly more frequent in patients with any adverse
event (P¼0.0052, OR¼13.12 [1.59–107.9] 95% CI), hepa-
totoxicity (P¼0.0083, OR¼ 15.75 [1.63–152] 95% CI),
and symptomatic side effects (P¼0.011, OR¼11.8
[1.35–103]95%CI). The TS 5’-UTR 3RC allele was also more
common in patients with an adverse event (P¼0.027) and
with a symptomatic side effect (P¼0.013) but not in those
with hepatotoxicity. However, there was no difference in
genotype distribution. Patients with hepatotoxicity had an
increased frequency of the TS 3’-UTR 6bp del mutation
(P¼0.012) and any variant genotype carried a significantly
risk of this adverse event (P¼ 0.015, OR¼8.4 [1.5–46.1]
95% CI).
The RFC 80A allele was significantly more common in
patients with an adverse event (P¼0.024). The frequency of
any RFC variant genotype was also higher in this group of
patients but not significantly so. The frequency of the MTHFR
1298C allelic variant was significantly reduced if hepatotoxi-
city had occurred (P¼0.042), whereas the distribution of the
677T allele was not changed. The frequency of MTHFR
variant genotypes did not differ between groups.
The occurrence of abnormal serum procollagen III (P3P)
results was investigated separately (data not shown). The
ATIC 347G allele was found to be more frequent in patients
with abnormal serum P3P values (P¼0.043), who also had
an increased number of the RFC 80A allele if they were not
taking folic acid (P¼0.027). No other mutation was found
to be more common in this group.
Patients who discontinued methotrexate owing to intoler-
able side effects (Table S4) had a higher frequency of the RFC
80A allele (P¼0.048), and any RFC variant genotype was
associated with a significant increase in risk of discontinuing
the drug (P¼0.01, OR¼ 2.40[1.21–4.75] 95% CI). The ATIC
347G allele frequency was also significantly increased in
these patients (P¼0.038), but no specific genotype was
significantly more frequent. A joint analysis of RFC and ATIC
confirmed the risk effect of both loci (P¼0.0076) with an OR
of 2.9 for the RFC 80A/ATIC 347G genotype; there was no
evidence of epistasis between the loci. In patients who
discontinued methotrexate and had not received folic acid
supplementation, the increase in RFC 80A frequency was
even more significant (P¼ 0.00021), with a higher risk of
discontinuation conferred by both variant homozygous and
heterozygous genotypes (P¼ 0.002, OR¼ 4.87 [1.69–14.05]
95% CI). In this group of patients, TS 5’-UTR 3R was also
significantly more common than in the group who continued
therapy with methotrexate (P¼ 0.033), but genotype distribu-
tion did not significantly differ between the two groups.
Haplotype analysis
The frequencies of MTHFR haplotypes were as follows:
677C/1298A 0.35, 677C/1298C 0.28, and 677T/1298A 0.36.
The 677T/1298C haplotype was very rare, with a frequency
of approximately 0.004. MTHFR SNPs are therefore in strong
linkage disequilibrium (D’¼1). The double heterozygous
genotype (677CT/1298AC) was significantly less frequent in
patients who experienced a raised ALT and were not taking
folate supplementation compared with patients with no
abnormal liver function tests (P¼0.033). Linkage disequili-
brium analysis of the TS loci showed four haplotypes: 5’-UTR
2R/3’-UTR 6bp ins 0.37, 5’-UTR 3R/3’-UTR 6bp ins 0.28,
5’-UTR 3R/3’-UTR 6bp del 0.25, and 5’-UTR 2R/3’-UTR 6bp
del 0.096. A D0 score of 0.4 meant that these two loci are in
some but not strong disequilibrium. The double homozygous
genotype was less frequent in patients who experienced an
adverse event, but not significantly so.
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DISCUSSION
This is the first study of methotrexate pharmacogenetics in
psoriasis. Eight polymorphisms in five enzymes involved in
folate, purine, and pyrimidine metabolism were correlated
with methotrexate efficacy and toxicity in patients with
severe psoriasis. We found consistently significant associa-
tions between polymorphisms in the RFC and TS genes and
clinical response to methotrexate.
Our results show that the TS 5’-UTR 3R allele was
associated with poor therapeutic response to methotrexate.
When all patients were analyzed, those with variant 5’-UTR 3R
genotypes were almost three times less likely to respond to









effects (%) P-value OR (95%CI)
RFC 80G4A
80A allele 58 (40) 108 (52) 0.025 1.63 (1.06–2.51) 37 (54) 0.053 80 (52) 0.043 1.60 (1.01–2.53)
80G allele 86 (60) 98 (48) 31 (46) 74 (48)
80 AA 15 (20) 32 (31) 0.132 13 (38) 0.057 23 (30) 0.205
80 GA + 80 GG 57 (80) 71 (69) 21 (62) 54 (70)
80 GA + 80 AA 43 (59) 76 (74) 0.049 1.89 24 (70) 0.279 57 (74) 0.063
80 GG 29 (41) 27 (26) 10 (30) 20 (26)
MTHFR 677C4T
677 T allele 54 (36) 75 (36) 0.92 30 (44) 0.319 55 (35) 0.751
677C allele 92 (64) 131 (64) 38 (56) 101 (65)
MTHFR A1298A4C
1298C allele 43 (29) 48 (23) 0.193 13 (19) 0.109 40 (26) 0.502
1298A allele 103 (71) 158 (77) 55 (81) 114 (74)
TS 50-UTR 28 bp repeats
3R allele 71 (51) 116 (56) 0.305 41 (60) 0.193 84 (55) 0.511
2R allele 69 (49) 90 (44) 27 (40) 70 (45)
TS 5’-UTR 3RG4C
3RC allele 30 (22) 59 (30) 0.092 19 (31) 0.193 44 (31) 0.106
All other alleles (inc. 2R) 106 (78) 135 (70) 43 (69) 100 (69)
TS 3’-UTR 6bp ins/del
6bp del allele 42 (30) 84 (41) 0.025 1.67 (1.06–2.63) 27 (40) 0.126 62 (40) 0.044 1.63 (1.01–2.65)
6bp ins allele 102 (70) 122 (59) 41 (60) 92 (60)
del/del 6 (8) 17 (16) 0.115 7 (21) 0.109 12 (16) 0.174
ins/del+ins/ins 66 (92) 86 (84) 27 (79) 65 (84)
ins/del+del/del 36 (51) 67 (65) 0.046 1.86 (1.00–3.44) 20 (59) 0.396 50 (64) 0.065
ins/ins 36 (49) 36 (35) 14 (41) 27 (36)
ATIC 347C4G
347G allele 87 (60) 136 (66) 0.283 45 (66) 0.42 104 (68) 0.2
347C allele 57 (40) 70 (33) 23 (34) 50 (32)
ADA 22G4A
22A allele 10 (7) 16 (8) 0.698 3 (4) 0.556 12 (8) 0.806
22G allele 134 (93) 182 (92) 65 (96) 144 (92)
ADA, adenosine deaminase; ATIC, 5-aminoimidazole-4-carboxamide ribonucleotide transformylase; CI, confidence interval; MTHFR, methylenetetrahy-
drofolate reductase; OR, odds ratio; RFC, reduced folate carrier; UTR, untranslated region.
1Genotype frequencies are provided only for alleles with a significantly different distribution.
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treatment than wild types. However, the exclusion of PPP
patients resulted in the loss of a correlation between the TS
5’-UTR 3R allele and poor response to methotrexate, making it
difficult to interpret this finding. It is possible that loss of
significance is due to lower statistical power or perhaps, may
reflect different pathophysiological mechanisms present in PPP.
An unexpected finding was the significant association
between the TS 5’-UTR 3R allele and the increased incidence
of methotrexate-induced toxicity in patients not receiving
folic acid. TS 5’-UTR 3R/3R homozygotes in this group were
13 times more likely to experience any adverse event, 15
times more likely to develop hepatotoxicity, and almost 12
times more likely to suffer a symptomatic side effect than
other genotypes. When a dominant model combining
homozygotes and heterozygotes was applied, the overall risk
of developing toxicity decreased to 3-fold and there was no
significant association with hepatotoxicity. Thus, homozyg-
osity for the 3R allele seems necessary for this mutation to
significantly increase the risk of hepatotoxicity in patients not
supplemented with folic acid. We suggest that the correlation
of this variant with a higher incidence of side effects could be
due to the increased transcriptional and/or translational
activity associated with the 3R allele, and possibly the
consequent depletion of the TS substrate 5,10-methylene-
THF, necessary for the methylation of homocysteine. In
addition, the 3R/3R genotype was associated with elevated
plasma homocysteine levels among individuals with low
dietary folate intake (Trinh et al., 2002; Kumagai et al., 2003).
However, recent evidence suggests that the addition of a
tandem repeat alone is not sufficient for enhanced transcrip-
tional activity of the TS gene, but that a specific consensus
element binding an upstream-stimulating factor is required
within the extra repeat to enhance transcription and hence
expression (Mandola et al., 2003). A G4C SNP at the 12th
nucleotide of the second repeat of the TS 5’-UTR 3R allele
abolishes upstream stimulating factor binding by disrupting
the upstream stimulating factor consensus sequence, resulting
in decreased transcriptional activity compared with wild
types (3RG), but similar to the 2R allele (Mandola et al.,
2003). In our study, the distribution of the C and G SNPs in
the second repeat of the 3R allele did not differ according to
the methotrexate efficacy or toxicity. However, when we
compared the frequency of the 3RC allele with that of all the
other alleles combined (3RG and 2R), we found that when
folic acid was not administered, patients carrying the 3RC
allele had an almost 3-fold increased risk of developing an
adverse event and a more than a 3-fold increased risk of
experiencing symptomatic side effects, but were not more
likely to have hepatotoxicity. These findings would suggest
that the mechanism by which TS contributes to the
development of toxicity varies with different adverse events,
and that increased TS expression may be related to the
development of hepatotoxicity, but not to that of sympto-
matic side effects.
We are the first to report that the TS 3’-UTR 6bp del allele
is more frequent in patients with an adverse event or a
symptomatic side effect, and in the absence of folate
supplementation is associated with an 8-fold increased risk
of developing a raised ALT level. This could be explained by
decreased TS , as the TS 3’-UTR 6bp del mutation leads to
lower TS mRNA expression in tumor cells (Ulrich et al., 2000;
Kumagai et al., 2003).
In our study, the RFC 80G4A SNP was not associated with
response to methotrexate. This is in conflict with the finding
reported by Dervieux et al. (2004) but is consistent with the
observation that the amino-acid sequence change (Arg27His)
in RFC resulting from the 80G4A SNP did not alter uptake
rates of methotrexate in pharmacokinetic studies (Chango
et al., 2000; Whetstine et al., 2001). The 80G4A SNP was
significantly and consistently associated with occurrence of
methotrexate-induced side effects. Altered methotrexate up-
take through the cell membrane now seems an unlikely
explanation for the observed increased incidence of adverse
events, and it may be that other mechanisms are involved.
No association was found between the MTHFR 677T SNP
and methotrexate toxicity, a finding supported by some
studies of RA patients, one prospective, (Kumagai et al.,
2003; Berkun et al., 2004), but contrasting with others (van
Ede et al., 2001; Urano et al., 2002). However, in those
studies which showed a significant association between the
677T allele and methotrexate-induced toxicity, the relative
risk was very small (1.25–2.38), suggesting a small effect for
this allele, and possibly reflecting insufficient power in our
study. In contrast, patients with the MTHFR 1298C allele and
those with the double heterozygous genotype (677CT/
1298AC) not receiving supplementation with folic acid were
less likely to develop hepatotoxicity, consistent with the
results of a previous study (Berkun et al., 2004). We speculate
that decreased enzyme activity may result in accumulation of
5,10-methylene-THF, necessary for thymidylate synthesis,
therefore counteracting the methotrexate-induced depletion
of THF and conferring protection against side effects.
The ATIC 347G allele was associated with abnormal
serum P3P results, an effect which followed a recessive
model, and increased 1.6-fold the likelihood of discontinuing
methotrexate because of side effects. However, this poly-
morphism was not associated with any other adverse events,
making the significance of these results uncertain.
We did not find any relationship between the ADA
22G4A SNP and methotrexate efficacy or toxicity. However,
in our study, the frequency of the 22A allele was much lower
(0.07) compared to that of the other polymorphisms studied
and power may be an issue.
Our findings confirm the importance of administering
concomitant folic acid to patients receiving methotrexate, as
(1) patients not receiving folic acid supplementation were
more than twice as likely to discontinue the drug and (2) in
most cases the impact of polymorphisms associated with
methotrexate-induced adverse events was attenuated or
disappeared if folic acid had been prescribed.
There are important limitations to this study. First of all this
is a retrospective study, which prevents objective and
systematic assessment of clinical progress and routine
documentation of adverse events. For the same reason it
was not possible to obtain pharmacokinetic data and
correlate polymorphisms with methotrexate or homocysteine
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blood levels. Furthermore, some of the study subgroups are
small and when results are corrected for multiple testing,
significance for some associations is lost. However, allowing
a correction factor for each polymorphism when the
correction for multiple testing is applied, the TS 5’-UTR 3R
and RFC 80 A alleles are still significantly associated with
methotrexate-induced toxicity and discontinuation in the no-
folate group. It is a concern that RFC genotypes were not in
Hardy–Weinberg equilibrium within the study population.
However, when patients with adverse events and patients
without adverse events when analyzed separately, both were
found to be in Hardy–Weinberg equilibrium. We cannot
exclude the possibility that this finding results from genotyp-
ing errors. Alternatively, RFC alleles may be in disequilibrium
with a locus conferring increased risk for psoriasis. In our
view, the lack of Hardy–Weinberg equilibrium is likely to be
the result of putting together two patient phenotypic groups
with very different genotype distribution and may indicate a
strong association between RFC 80 A and adverse events.
Despite important limitations, our findings are consistent
within the study and/or are supported by previous studies. We
have thus identified several polymorphisms in enzymes
involved in folate, purine, and pyrimidine metabolism,
especially TS and RFC, which have a significant impact on
clinical response to methotrexate, and therefore are potentially
useful in determining valid predictive markers of methotrexate
efficacy and toxicity in psoriasis. Future work should be
directed toward exploring the differential impact of these
polymorphisms in a large prospective cohort of psoriasis
patients commencing systemic therapy with methotrexate.
MATERIALS AND METHODS
This study adheres to the Declaration of Helsinki Principles and was
approved by the Research Ethics Committee of Guy’s and St Thomas’
Hospitals in London. Informed written consent was obtained from all
patients included in this study.
Study population
Adult patients (age 18 years and over) with psoriasis who had
currently or previously been treated with methotrexate monotherapy
were recruited via dermatology clinics, pharmacy lists, and a
procollagen III test database at St Thomas’ Hospital, London, UK.
Patients were retrospectively classified according to clinical re-
sponse to therapy with methotrexate, development of methotrexate-
induced adverse events, and/or methotrexate discontinuation owing
to any intolerable side effect. Patients who had completed at least 3
months of therapy with methotrexate were classified as responders (if
there was an explicit statement in the case notes documenting
significant improvement or clearance of psoriasis and/or 475%
improvement in the Psoriasis Area Severity Index), non-responders (if
there was an explicit statement in their case notes that therapy was
stopped because of lack of efficacy and/or o50% improvement in
Psoriasis Area Severity Index), or indeterminate (patients failing to
fulfil the above criteria). Methotrexate-induced adverse events were
categorized as (1) hepatotoxicity, that is, raised ALT (a raise in ALT
more than three times the upper limit of normal within 3 years of
starting methotrexate), resulting in dose reduction or termination of
therapy; (2) bone marrow toxicity, that is, a decrease in hemoglobin,
white cell count, or platelets to o75% of baseline, or white cell
count o3.5, and/or platelets o120 within 3 years of starting
methotrexate, resulting in dose reduction or termination of therapy;
(3) symptomatic side effects, that is, nausea, diarrhea, hair loss,
mouth ulcers, depression, headache, dizziness, or other side effects
sufficiently significant to be documented in the clinical case notes;
(4) abnormal serum P3P, that is, P3P48mg/l on two consecutive
occasions, or 44.2 mg/l at least three times in a year, within 3 years
of starting methotrexate (Chalmers et al., 2005). General methotrex-
ate-induced toxicity was defined as the presence of at least one
adverse event excluding abnormal serum P3P. The abnormal serum
P3P category was analyzed separately in view of the relatively recent
introduction of this monitoring test for methotrexate-induced hepatic
fibrosis, and its unavailability in many dermatology centres.
Methotrexate withdrawal was defined as discontinuation of metho-
trexate owing to any adverse event. Concomitant therapy with folic
acid was documented for each patient.
Methods
Venous blood for DNA extraction was collected in EDTA tubes and
stored at –70oC. Genomic DNA was isolated from whole blood using
standard techniques (Young et al., 2003). DNA was amplified with
recombinant Taq DNA polymerase recombinant (Invitrogen Ltd,
Paisley, UK) in a total volume of 20 ml with 0.5mM of each primer.
Reactions were supplemented with 5% DMSO.
Methods for genotyping the TS 5’-UTR (Marsh et al., 1999) TS
5’-UTR 3R G4C (Mandola et al., 2003) RFC-1 80G4A (Dervieux
et al., 2004), MTHFR 677C4T and MTHFR 1298A4C (Breen et al.,
2005) polymorphisms have been published previously.
ATIC 347C4G. The ATIC 347 C4G mutation was amplified
using primers forward 5’-TCCCTTTGTAAAGACAGTGGCTTCTC
CAGCAGTAA-3’ and reverse 5’-AATTATAGTAATCCCAAAACACA
ATCCAGAAGTAG-3’. The mismatch forward primer creates an
AlwNI site when the 347 C4G mutation is present. The thermo-
cycler profile consisted of 35 cycles of 941C 30 seconds, 541C
30 seconds, and 721C 30 seconds. The PCR product was micro-
dialysed for 3 minutes on Millipore VSP filters and digested with
AlwNI at 371C overnight. Samples were separated on a 2.5%
Agarose 1000 (Invitrogen Ltd, Paisley, UK).
ADA 22G4A. The ADA 22 G4A mutation destroys a TaqI site
and was amplified with primers forward, 5’-CACGAGGGCACC
ATGGCCCAGA-3’ and reverse 5’-CCCATTGTCCCTGATTAGCCC
GCAAG-3’. Thermocycler profile consisted of 35 cycles of 941C
30 seconds, 631C 30 seconds, and 721C 30 seconds. The PCR
product was microdialysed for 3 minutes on Millipore VSP filters
and digested with TaqI at 651C overnight. Products were separated
on a 2.5% Agarose 1000.
The TS 3’-UTR 6bp ins/del. Sample were amplified twice. Both
amplifications shared the same forward primer 5’-ATTACAA
CAGGTCGTACAATTATGGC-3’, and differed in the reverse primer.
The positive 5’- CTTTATTATAGCAACATATAAAACAACTATAACT-3’
primer was designed to anneal when the 6-bp sequence was present,
and the negative 5’-TTTATTATAGCAACATATAAAACAACTATA
AAGT-3’ reverse primer annealed specifically to the DNA sequence
when the 6-bp fragment was absent. The fragments amplified with
each set of primers was approximately 673-bp long. Each sample
was run on consecutive lanes on a 2% standard agarose gel and
scored for the presence or absence of the 673-bp band.
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A PCR blank and genotype controls were included in each series
of PCR reactions.
The genotyping success rate for all polymorphisms studied was
98–99.5%, with the exception of the TS 5’-UTR 3R G4C SNP
(93.5%).
Statistical analysis
Patients were assigned to different groups according to their outcome
to therapy (clinical response, development of side effects, and/or
drug withdrawal following therapy with methotrexate). A subana-
lysis comparing these different groups was also carried out in
patients not receiving folic acid. When analysing methotrexate
efficacy, a further analysis was carried out with the exclusion of
patients with palmoplantar pustular psoriasis, as there is increasing
evidence that, although associated with psoriasis, this is a separate
disease with different pathophysiological mechanisms. The number
of alleles for each polymorphism was counted in each patient group.
Allele frequencies were compared between groups in 2 2
contingency tables using the w2 test or the two-tailed Fisher’s exact
test (if o5 patients in the study group). A P-value of o0.05 was
considered significant. Genotype frequencies were calculated and
compared when a significant difference in allele distribution was
detected. All genotypes were in Hardy–Weinberg equilibrium except
for the RFC 80 genotypes. However, when RFC 80G4A genotypes
of patients with adverse events and those without adverse events
were analyzed as separate groups, genotypes were in Hardy–Wein-
berg equilibrium for both groups.
For the phenotypes where at least two SNPs or mutations were
significant, both polymorphisms were analyzed together to test for
an interaction or a joint effect (where each SNP increases the risk
of the phenotype occurring, independently). This was carried out
using Unphased (Dudbridge, 2003) software, which does not
provide confidence intervals for ORs. The same program was used
to carry out linkage disequilibrium analysis of the MTHFR and
TS gene.
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methotrexate intracellular interactions.
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